Kinnate Biopharma Inc. Common Stock
KNTE
KNTE was delisted on the 2nd of April, 2024.
73 hedge funds and large institutions have $493M invested in Kinnate Biopharma Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 13 reducing their positions, and 15 closing their positions.
108% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 13
6% more capital invested
Capital invested by funds: $465M → $493M (+$27.7M)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
7% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 15
4% less funds holding
Funds holding: 76 → 73 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$9.14M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.97M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$2.55M |
| 4 |
BlackRock
New York
|
+$2.27M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$1.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$6.85M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.28M |
| 3 |
HF
HRT Financial
New York
|
-$1.03M |
| 4 |
Swiss National Bank
Zurich,
Switzerland
|
-$270K |
| 5 |
Two Sigma Investments
New York
|
-$259K |
KNTE Hedge Fund Activity: Q2 2022 in Review
73 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q2 2022, worth a combined $493M — up 6% from $465M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of KNTE and 14 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 27 added.
The largest buyer was Lynx1 Capital Management, adding an estimated $9.14M. The largest seller was Deerfield Management, cutting an estimated $6.85M.
- 73 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q2 2022, down from 76 in Q1 2022.
- Funds reported $493M of Kinnate Biopharma Inc. Common Stock stock for Q2 2022, up 6% quarter-over-quarter.
- 14 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q2 2022 and 15 closed out, a net change of -1 holder.
- The largest Kinnate Biopharma Inc. Common Stock buyer in Q2 2022 was Lynx1 Capital Management, an estimated $9.14M added.
- The largest Kinnate Biopharma Inc. Common Stock seller in Q2 2022 was Deerfield Management, an estimated $6.85M sold.
Based on aggregated 13F filings for Q2 2022.